Darifenacin Hydrobromide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Darifenacin Hydrobromide |
| DrugBank ID | DB00496 |
| Brand Names (EU) | Emselex |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.79% |
Approved Indication (EMA)
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | overactive bladder (disease) | 99.79% | DL |
| 2 | polycystic kidney disease 3 with or without polycystic liver disease | 96.93% | DL |
| 3 | thoracic malformation | 96.13% | DL |
| 4 | renal-hepatic-pancreatic dysplasia | 96.06% | DL |
| 5 | Joubert syndrome with renal defect | 95.84% | DL |
| 6 | low compliance bladder | 95.69% | DL |
| 7 | adult familial nephronophthisis-spastic quadriparesia syndrome | 95.52% | DL |
| 8 | karyomegalic interstitial nephritis | 95.28% | DL |
| 9 | polycystic kidney disease | 92.37% | DL |
| 10 | primary hereditary glaucoma | 86.73% | DL |
| 11 | respiratory failure | 86.39% | DL |
| 12 | tic disorder | 84.26% | DL |
| 13 | communication disorder | 83.58% | DL |
| 14 | hypotrichosis simplex of the scalp | 83.08% | DL |
| 15 | developmental disorder of mental health | 83.01% | DL |
| 16 | fetal nicotine spectrum disorder | 82.32% | DL |
| 17 | stereotypic movement disorder | 82.32% | DL |
| 18 | blepharospasm | 82.24% | DL |
| 19 | parkinsonian disorder | 82.13% | DL |
| 20 | bladder neck obstruction | 81.89% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.